BIVICTRIX
THERAPEUTICS PLC
("BiVictriX" or the "Company")
Publication of 2023 Annual
Report and Notice of AGM
Alderley Park, 26 June 2024 -
BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and
development company applying an innovative, proprietary approach to
develop a new class of highly selective, next generation cancer
therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs),
which exhibit superior potency, whilst eliminating
treatment-related toxicities, announces that it has
published and posted to shareholders the annual report and
financial statements for the year ended 31 December 2023 ("Annual
Report and Accounts"), and Notice of Annual General Meeting
("AGM").
BiVictriX will hold its AGM at the Company's
registered office at Mereside Alderley Park, Alderley Edge,
Manchester, SK10 4TG on 24 July 2024 at 3.00 p.m. (BST).
The Annual Report and Accounts and
Notice of AGM are also available to view on, and download from, the
Company's website at https://www.bivictrix.com/investor-centre.
|
ENDS
For
more information, please contact:
|
BiVictriX
Therapeutics plc
|
|
|
|
Tiffany Thorn, Chief Executive
Officer
Michael Kauffman, Non-Executive
Chairman
|
Email: info@bivictrix.com
|
|
|
|
|
|
|
SP Angel
Corporate Finance LLP (NOMAD and Broker)
|
Tel: +44 (0)
20 3470 0470
|
|
|
David Hignell, Caroline
Rowe, Kasia Brzozowska (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
Tel: +44 (0)
20 7886 2500
|
|
|
Rupert Dearden/Freddy Crossley/Emma
Earl
ICR
Consilium
|
|
|
|
Mary-Jane Elliott, Namrata Taak,
Max Bennett, Emmalee Hoppe
|
Tel: +44 (0) 20 3709
5700
Email: Bivictrix@consilium-comms.com
|
|
|
|
|
|
|
|
About
BiVictriX Therapeutics plc
BiVictriX is a UK-based drug
discovery and development company which is focused on leveraging
clinical experience to develop a new class of highly selective,
next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related
toxicities.
The Company utilises a
first-in-class approach to generate a proprietary pipeline of
Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from
healthy cells.
BiVictriX has established a growing
proprietary library of cancer-specific Bi-Cygni® fingerprints,
which enable the Company to target a diverse array of different
cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug
Conjugate therapeutic design, to develop more effective and safer
therapeutics to target cancers that are expected to constitute
orphan indications and areas of high unmet medical need.
Find out more about BiVictriX online
at www.bivictrix.com